COMPANY RESEARCHThe 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
Net proceeds from shares actually sold through June 30, not a single venture round. Shelf or ATM authorized capacity is not treated as funds raised.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| cemsidomide（CFT7455） | IKZF1/3 · Multiple myeloma | Phase 2 | Human results reported by the source; see facts and original materials for type and quality |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
C4 Therapeutics described a DNA-encoded library that incorporates its cereblon-binding ligand collection for target-first molecular glue discovery. The company reported known and novel VAV1 degrader hits as platform validation, while stating that it would not advance VAV1 without a partner. This is a discovery-platform update, not the clinical entry of a new drug candidate.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.